Treatment of ErbB2 breast cancer by mitochondrial targeting

BACKGROUND: ErbB2 breast cancer still remains an unmet need due to primary and/or acquired resistance to current treatment strategies. MEDICA compounds consist of synthetic long-chain α,ω-dicarboxylic acids previously reported to suppress breast cancer in PyMT transgenic mice. METHODS: MEDICA effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Eldad, Sophia, Hertz, Rachel, Vainer, Gilad, Saada, Ann, Bar-Tana, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362624/
https://www.ncbi.nlm.nih.gov/pubmed/32695336
http://dx.doi.org/10.1186/s40170-020-00223-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362624/
https://www.ncbi.nlm.nih.gov/pubmed/32695336
http://dx.doi.org/10.1186/s40170-020-00223-8

Ejemplares similares